A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance, Safety, and Timing of Postdose Imaging of ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Solid Tumors Undergoing Routine Surgery
Phase of Trial: Phase II
Latest Information Update: 04 Sep 2019
Price : $35 *
At a glance
- Drugs ONM 100 (Primary)
- Indications Bladder cancer; Breast cancer; Colorectal cancer; Head and neck cancer; Ovarian cancer; Prostate cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Diagnostic use
- Sponsors OncoNano Medicine
- 27 Aug 2019 Planned End Date changed from 31 Oct 2019 to 31 Jan 2020.
- 27 Aug 2019 Planned primary completion date changed from 30 Sep 2019 to 31 Dec 2019.
- 27 Aug 2019 Status changed from not yet recruiting to recruiting.